Pricing, Profits, and Technological Progress in the Pharmaceutical Industry
- 1 August 1993
- journal article
- Published by American Economic Association in Journal of Economic Perspectives
- Vol. 7 (3) , 97-115
- https://doi.org/10.1257/jep.7.3.97
Abstract
The decades-old debate over pharmaceutical industry prices, profits, and innovation has again intensified. A number of events coalesced to refocus public interest on pharmaceuticals. Contributing to public concern were Bureau of Labor Statistics price index increases for pharmaceuticals far outpacing those for the products of other industries. Another prominent characteristic of the pharmaceutical industry has been its extraordinarily high reported profitability. This article examines the phenomena that precipitated the current pharmaceuticals debate, their historical antecedents, and the principal questions at issue. In the author's considered judgment, a pell-mell march toward regulation of pharmaceutical industry pricing could seriously impair the industry's incentives for investment in new products.Keywords
This publication has 9 references indexed in Scilit:
- Pricing, Patent Loss and the Market for PharmaceuticalsSouthern Economic Journal, 1992
- Brand Loyalty, Entry, and Price Competition in Pharmaceuticals after the 1984 Drug ActThe Journal of Law and Economics, 1992
- Medical Care Costs: How Much Welfare Loss?Journal of Economic Perspectives, 1992
- Welfare Effects of Global Patent ProtectionEconomica, 1992
- Cost of innovation in the pharmaceutical industryJournal of Health Economics, 1991
- A New Look at the Returns and Risks to Pharmaceutical R&DManagement Science, 1990
- Regulation and Firm Size: FDA Impacts on InnovationThe RAND Journal of Economics, 1990
- Estimating the Effects of Regulation on Innovation: An International Comparative Analysis of the Pharmaceutical IndustryThe Journal of Law and Economics, 1978
- New Methods in Statistical EconomicsJournal of Political Economy, 1963